Solentim Turns 10: Celebrating a decade of progress and pioneering advances
Solentim is delighted to celebrate its 10-year anniversary today. Despite the uncertain times we currently live in, Solentim continues to forge ahead, and today celebrates another successful year, and a decade of growth and progress.
For all of this success we thank our staff, past and present, and all our customers
Over the past decade, the Company has gone from strength to strength and we are delighted to report that in the past few years we have sold to all of the world’s top 10 pharma companies. We have continued to invest in and strengthen our sales network across North America, Europe and Asia, and now have hundreds of customers in over 20 countries.
Focussed on product innovation
Since 2010 we have launched several new products tailored to meet the needs of our customers and partnered with leading experts to further strengthen our offering. 2011 saw the launch of the Cell Metric®, our small benchtop high-resolution whole well imaging system developed for cell line development, outgrowth optimisation studies and cell culture processing. This was closely followed by the introduction of the Cell Metric® CLD, our automated premium version of the Cell Metric with a built-in, incubated plate loader for unattended imaging of 10 plates in a cassette.
In 2017 we launched the VIPS™ (Verified in-situ plate seeding), our unique all-in-one instrument performing both single-cell seeding and whole well imaging. Most recently, in 2019 we partnered with SAL Scientific to bring our customers a unique range of cell culture growth supplements for cell line development.
Growth and globalisation
The last 10 years have also seen significant expansion both internally and globally. In 2015 we opened our US office in order to better support our valued customer base in the United States. We have also created and nurtured a long-term relationship and distributor network in Asia. In fact, of the five mAbs approved by 2019 by the National Medical Products Administration in China, four of these used the Solentim Cell Metric®, or Cell Metric CLD whole-cell imaging systems to provide assurance of clonality.
In 2016 we hit the milestone of selling to our 100th customer. In 2018 we were awarded two Queen’s Awards for Enterprise, regarded as the UK’s most prestigious business awards, and were also named as one of the top 50 fastest growing UK technology companies of 2018 in the Deloitte UK Technology Fast 50 list, following a 1,106% revenue growth over the previous 4 years.
Over the past 10 years we have worked hard to grow the company and are proud to employ over 50 staff members.
This year we have continued to strengthen our leadership team, enhancing our capability, skill and experience to better support our global customer base. Mark Truesdale joined the Company in October 2019 as Chief Marketing Officer and was named CEO in March 2020.
We are fortunate to work with industry leaders in a wide variety of fields, finding new ways to support them and their innovative research. Our customers are working to develop monoclonal antibody vaccines, biotherapeutics, biosimilars and gene therapies, utilising cutting edge gene editing and cell engineering to make a global difference. Without the support of all these innovators, Solentim would not be where it is today, and for this we would like to thank all our customers, past, present and future.
Following a decade of commitment to the Company and the industry, Solentim has become the market leader in solutions for documented monoclonality assurance to the biologics markets. We would not have achieved such success without the hard work and dedication of all our staff, both those that have left and those still with us – thank you!
We look forward to seeing what the next decade will hold for the Company and our team. Get in touch to find out more about Solentim and how we can accelerate your cell line development workflows.